Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents.
Analgesics
/ pharmacology
Anticoagulants
/ pharmacology
Antiviral Agents
/ pharmacokinetics
Betacoronavirus
COVID-19
Coronavirus Infections
/ drug therapy
Dose-Response Relationship, Drug
Drug Interactions
Extracorporeal Membrane Oxygenation
/ methods
Humans
Hypnotics and Sedatives
/ pharmacology
Pandemics
Pneumonia, Viral
/ drug therapy
Renal Replacement Therapy
/ methods
SARS-CoV-2
Therapeutic Index, Drug
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
30
7
2020
medline:
31
10
2020
entrez:
30
7
2020
Statut:
ppublish
Résumé
There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological evidence, focusing on (1) the pharmacokinetics (PK) of potential antiviral therapies; (2) coronavirus-specific pharmacodynamics (PD); (3) PK and PD interactions between proposed combination therapies; (4) pharmacology of major supportive therapies; and (5) anticipated drug-drug interactions (DDIs). We found promising in vitro evidence for remdesivir, (hydroxy)chloroquine and favipiravir against SARS-CoV-2; potential clinical benefit in SARS-CoV-2 with remdesivir, the combination of lopinavir/ritonavir (LPV/r) plus ribavirin; and strong evidence for LPV/r plus ribavirin against Middle East Respiratory Syndrome (MERS) for post-exposure prophylaxis in healthcare workers. Despite these emerging data, robust controlled clinical trials assessing patient-centred outcomes remain imperative and clinical data have already reduced expectations with regard to some drugs. Any therapy should be used with caution in the light of potential drug interactions and the uncertainty of optimal doses for treating mild versus serious infections.
Identifiants
pubmed: 32725382
doi: 10.1007/s40262-020-00924-9
pii: 10.1007/s40262-020-00924-9
pmc: PMC7385074
doi:
Substances chimiques
Analgesics
0
Anticoagulants
0
Antiviral Agents
0
Hypnotics and Sedatives
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1195-1216Subventions
Organisme : Medical Research Council
ID : MR/M008665/1
Pays : United Kingdom
Références
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
ACS Omega. 2018 Dec 31;3(12):18132-18141
pubmed: 30613818
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Acta Trop. 2002 Jul;83(1):49-61
pubmed: 12062793
J Crit Care. 2012 Dec;27(6):741.e9-18
pubmed: 22520488
PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389
pubmed: 28231247
Antimicrob Agents Chemother. 2013 Apr;57(4):1743-55
pubmed: 23357765
Hong Kong Med J. 2003 Dec;9(6):399-406
pubmed: 14660806
Blood Purif. 1993;11(2):99-107
pubmed: 8274246
Lancet Infect Dis. 2014 Jun;14(6):498-509
pubmed: 24768475
Int J Antimicrob Agents. 2014 Dec;44(6):528-32
pubmed: 25288266
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Arthritis Care Res (Hoboken). 2016 Sep;68(9):1295-302
pubmed: 26749299
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Am J Med. 1983 Jul 18;75(1A):40-5
pubmed: 6869410
J Hosp Infect. 2019 Jan;101(1):42-46
pubmed: 30240813
Drug Discov Ther. 2020;14(1):58-60
pubmed: 32147628
Curr Clin Pharmacol. 2013 Feb 1;8(1):39-45
pubmed: 22946871
Hepatology. 2006 May;43(5):943-53
pubmed: 16761329
AIDS. 2001 Nov 23;15(17):2221-9
pubmed: 11698694
Biosci Trends. 2020 Mar 16;14(1):64-68
pubmed: 32037389
Clin Pharmacokinet. 1990 Nov;19(5):390-9
pubmed: 1702693
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
Expert Opin Drug Metab Toxicol. 2015;11(12):1803-19
pubmed: 26419922
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041
pubmed: 32936252
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Antiviral Res. 2014 May;105:17-21
pubmed: 24583123
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Chin Med J (Engl). 2020 May 5;133(9):1132-1134
pubmed: 32149772
J Clin Pharm Ther. 2017 Dec;42(6):661-671
pubmed: 28948652
Thorax. 2004 Mar;59(3):252-6
pubmed: 14985565
Cell Discov. 2020 Mar 18;6:16
pubmed: 32194981
Clin Pharmacokinet. 2001;40(11):833-68
pubmed: 11735605
Biomed Pharmacother. 2018 Mar;99:921-930
pubmed: 29710492
J Med Virol. 2012 Jan;84(1):170-81
pubmed: 22028179
Clin Pharmacokinet. 2007;46(12):997-1038
pubmed: 18027987
Acta Anaesthesiol Scand. 2001 Sep;45(8):929-34
pubmed: 11576041
JAMA Netw Open. 2020 Apr 24;3(4):e208857
pubmed: 32330277
Antimicrob Agents Chemother. 2011 Feb;55(2):473-7
pubmed: 21098255
J Gen Virol. 2014 Mar;95(Pt 3):571-577
pubmed: 24323636
Clin Pharmacokinet. 1998 Oct;35(4):275-91
pubmed: 9812178
Nat Rev Nephrol. 2011 Apr;7(4):226-35
pubmed: 21343897
Biol Pharm Bull. 2008 Nov;31(11):1985-9
pubmed: 18981560
Cell Discov. 2020 May 2;6:28
pubmed: 32373347
Travel Med Infect Dis. 2020 May - Jun;35:101738
pubmed: 32387409
Br J Clin Pharmacol. 2015 Apr;79(4):650-9
pubmed: 25297637
Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
pubmed: 31925415
Antimicrob Agents Chemother. 2011 Jun;55(6):2775-82
pubmed: 21422211
J Med Virol. 2020 Jun;92(6):556-563
pubmed: 32104907
Lancet. 2020 May 22;:
pubmed: 32450107
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
J Infect. 2013 Dec;67(6):606-16
pubmed: 24096239
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8
pubmed: 15607755
AIDS. 2008 Oct 1;22(15):1919-27
pubmed: 18784455
Eur J Clin Pharmacol. 2019 Feb;75(2):207-216
pubmed: 30291369
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004
J Vet Pharmacol Ther. 2004 Dec;27(6):441-53
pubmed: 15601439
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Pharmacol Toxicol. 1998 Sep;83(3):135-8
pubmed: 9783333
Antiviral Res. 2018 Mar;151:97-104
pubmed: 29289666
Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84
pubmed: 24841269
Eur J Clin Pharmacol. 2012 Apr;68(4):415-8
pubmed: 22037562
Antivir Ther. 2018;23(5):457-461
pubmed: 29185991
Anal Bioanal Chem. 2008 Jun;391(3):1063-71
pubmed: 18392693
J Lab Clin Med. 1976 Jul;88(1):87-90
pubmed: 932536
Expert Opin Drug Discov. 2019 Apr;14(4):397-412
pubmed: 30849247
J Interferon Cytokine Res. 1999 Oct;19(10):1117-23
pubmed: 10547151
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Xenobiotica. 1994 Jan;24(1):79-92
pubmed: 8165824
Antimicrob Agents Chemother. 2020 May 21;64(6):
pubmed: 32312781
Ther Drug Monit. 1986;8(3):285-7
pubmed: 3750371
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Antivir Ther. 2016;21(5):455-9
pubmed: 26492219
World J Pediatr. 2020 Jun;16(3):223-231
pubmed: 32034659
Clin Microbiol Infect. 2020 Jul;26(7):917-921
pubmed: 32344167
Ther Adv Psychopharmacol. 2017 Dec;7(12):251-264
pubmed: 29201344
Clin Infect Dis. 2020 Dec 15;71(12):3232-3236
pubmed: 32435791
Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25
pubmed: 15144898
J Antimicrob Chemother. 2016 Jun;71(6):1597-600
pubmed: 26869690
J Gastroenterol. 2014 Mar;49(3):388-99
pubmed: 23720090
Curr Opin Infect Dis. 2019 Apr;32(2):176-186
pubmed: 30724789
J Clin Virol. 2004 Sep;31(1):69-75
pubmed: 15288617
Lancet Infect Dis. 2014 Nov;14(11):1090-1095
pubmed: 25278221
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Int J Clin Pharmacol Ther. 2013 May;51(5):423-32
pubmed: 23391367